# BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL

> **NCT07678229** · PHASE3 · RECRUITING · sponsor: **Rong Tao** · enrollment: 150 (estimated)

## Conditions studied

- Extranodal NK/T-cell Lymphoma

## Interventions

- **DRUG:** GELAD regimen
- **DRUG:** MEDA regimen
- **DRUG:** LEAP regimen
- **DRUG:** High-dose methotrexate
- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT07678229
- **Lead sponsor:** Rong Tao
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-11
- **Primary completion:** 2031-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678229, "BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*